DrugBiological
Volrustomig clinical trials
Also written MEDI5752.
- studies test it
- 19
- open now
- 7
- in phase 3
- 4
- first study started
- 2018
Keep track of what changes. Save the volrustomig studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2023 (6)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 1 |
| 2025 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 5
- Phase 2
- 8
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 3
AstraZeneca (12) · MedImmune LLC (2) · Presage Biosciences (2) · Institut Bergonié (1) · CCTU- Cancer Theme (1) · University of Chicago (1)
Often tested with
Tested in the same studies.
Rilvegostomig (7) · Carboplatin (4) · Cisplatin (3) · Pemetrexed (3) · Sabestomig (2) · Pembrolizumab (2) · Tilatamig samrotecan (2) · Durvalumab (2)
Studies
Open first, then newest update. How each study uses volrustomig is read from its arms, and is right about nine times in ten.
Testing it · 19
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Written as Volrustomig
- A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent ChemoradiotherapyRecruitingPhase 3AstraZenecaNCT06129864Written as volrustomig
- Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)RecruitingPhase 3AstraZenecaNCT06079671Written as Volrustomig
- WIRE - Novel Treatments in Renal Cell CancerRecruitingPhase 2CCTU- Cancer ThemeNCT03741426Written as Volrustomig
- Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2AstraZenecaNCT05702229Written as Volrustomig
- Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck CancerRecruitingPhase 2University of ChicagoNCT07065630Written as Volrustomig
- MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.Not yet recruitingPhase 2Institut BergoniéNCT05888857Written as MEDI5752
- MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaActive, not recruitingPhase 3AstraZenecaNCT06097728Written as Volrustomig
- A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerActive, not recruitingPhase 2AstraZenecaNCT06792695Written as Volrustomig
- A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Active, not recruitingPhase 3AstraZenecaNCT05984277Written as Volrustomig
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingPhase 2AstraZenecaNCT05775159Written as Volrustomig
- A Study to Evaluate MEDI5752 in Subjects With Advanced Solid TumorsActive, not recruitingPhase 1MedImmune LLCNCT03530397Written as MEDI5752
- A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)Active, not recruitingPhase 2AstraZenecaNCT06943833Written as Volrustomig
- A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCActive, not recruitingPhase 1AstraZenecaNCT07000149Written as Volrustomig
- PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCCCompletedEarly Phase 1Presage BiosciencesNCT06366451Written as Volrustomig
- Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesActive, not recruitingEarly Phase 1Presage BiosciencesNCT04541108Written as Volrustomig
- A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive, not recruitingPhase 1AstraZenecaNCT03819465Written as MEDI5752
- MEDI5752 in Japanese Patients With Advanced Solid Tumors.CompletedPhase 1AstraZenecaNCT05685472Written as MEDI5752
- A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell CarcinomaActive, not recruitingPhase 1MedImmune LLCNCT04522323Written as MEDI5752
Given in every arm · 6 — volrustomig is usual care beside what is tested
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)RecruitingPhase 2AstraZenecaNCT05489211Written as Volrustomig
- Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsRecruitingPhase 2AstraZenecaNCT06535607Written as Volrustomig
- Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCRecruitingPhase 1AstraZenecaNCT04686305Written as Volrustomig
- Volrustomig Priming Regimens Exploratory Phase II Platform StudyActive, not recruitingPhase 2AstraZenecaNCT06448754Written as Volrustomig
- Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Active, not recruitingPhase 2AstraZenecaNCT04379596Written as Volrustomig
- Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 1AstraZenecaNCT04612751Written as MEDI5752
Codes
What other systems call volrustomig · ClinicalTrials.gg INT017034
- UNII (FDA) K96EGJ218NVOLRUSTOMIGOne source FDA
- NCI Thesaurus C171937VolrustomigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | K96EGJ218N | VOLRUSTOMIG | One source FDA |
| NCI Thesaurus | C171937 | Volrustomig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.